Zealand Pharma A/S (OTCMKTS:ZLDPF) Rating Lowered to Strong Sell at Zacks Research

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Thursday,Zacks.com reports.

Other equities analysts have also issued research reports about the company. Wells Fargo & Company restated an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday. Wolfe Research lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Berenberg Bank cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Finally, Jefferies Financial Group downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Get Zealand Pharma A/S alerts:

Read Our Latest Analysis on ZLDPF

Zealand Pharma A/S Price Performance

Shares of ZLDPF opened at $52.68 on Thursday. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. Zealand Pharma A/S has a 12 month low of $35.93 and a 12 month high of $83.12. The firm’s 50 day moving average is $45.69 and its 200-day moving average is $49.49. The stock has a market capitalization of $3.77 billion, a PE ratio of 8.74 and a beta of 0.88.

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported $8.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $8.47. The business had revenue of $698.62 million during the quarter, compared to analysts’ expectations of $692.12 million. Zealand Pharma A/S had a return on equity of 18.53% and a net margin of 58.86%. Equities research analysts forecast that Zealand Pharma A/S will post 2.37 EPS for the current year.

Zealand Pharma A/S Company Profile

(Get Free Report)

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.

Read More

• Five stocks we like better than Zealand Pharma A/S
• MarketBeat Week in Review – 08/10 – 08/14
• Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
• Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
• NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.